About: Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial
Creator	Jayasinghe, Saroj Malavige, Neelika Balasooriya, Priyantha De Silva, Arjuna De Silva, Hithanadura Duminda, Kaluthanthri Ediriweera, Dileepa Kularathne, Senanayake Lekamwasam, Sarath Niriella, Madunil Premarathne, Ranjan Siribaddana, Sisira Wanigasuriya, Kamani
Source	Medline; PMC
abstract	BACKGROUND: The first case of a coronavirus 2019 (COVID-19) infection in a Sri Lankan was reported on March 11, 2020. The situation in Sri Lanka changed with the rapid increase of personnel contracting COVID-19 in a naval base camp that housed more than 4000 people. This provided a unique opportunity to study the effectiveness of hydroxychloroquine (HCQ) for post-exposure prophylaxis (PEP), while taking stringent, non-pharmacologic, public health measures to prevent spread. Our aim is to study the effectiveness and safety of HCQ for PEP among naval personnel with exposure to COVID-19-positive patients. METHODS/DESIGN: This is a placebo-controlled, randomized, clinical trial carried out in the naval base camp and quarantine centers of the Sri Lanka Navy, Ministry of Defense, Sri Lanka. Navy personnel who are exposed to a patient with confirmed COVID-19 infection but test negative for the virus on reverse real-time polymerase chain reaction (rRT-PCR) at recruitment will be randomized, 200 to each arm, to receive HCQ or placebo and monitored for the development of symptoms or rRT-PCR positivity for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus for 14 days. DISCUSSION: This trial will provide high-quality evidence of the effectiveness and safety of HCQ as PEP for COVID-19. The study design is unique due to the circumstances of the outbreak in a confined area among otherwise healthy adults, at a relatively early stage of its spread. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry (SLCTR) SLCTR/2020/011. Registered on 04 May 2020
has issue date	2020-08-27(xsd:dateTime)
bibo:doi	10.1186/s13063-020-04659-7
bibo:pmid	32854751
has license	cc-by
sha1sum (hex)	7956f68c85f94e19da4c42ca7e60e620f78ab61a
schema:url	https://doi.org/10.1186/s13063-020-04659-7
resource representing a document's title	Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial
has PubMed Central identifier	PMC7450681
has PubMed identifier	32854751
schema:publication	Trials
resource representing a document's body	covid:7956f68c85f94e19da4c42ca7e60e620f78ab61a#body_text
is schema:about of	named entity 'positive' named entity 'COVID-19' named entity 'PEP' named entity 'protocol' named entity 'CORONAVIRUS' named entity 'MARCH' named entity 'PROVIDED' named entity 'UNIQUE' named entity 'CHANGED' named entity 'infection' named entity 'unique' named entity 'Our' named entity '2019' named entity 'randomized' named entity 'post-exposure prophylaxis' named entity 'infection' named entity 'Sri Lanka' named entity 'coronavirus 2019' named entity 'COVID-19' named entity 'Sri Lanka' named entity 'pharmacologic' named entity 'HCQ' named entity 'HCQ' named entity 'post-exposure prophylaxis' named entity 'randomized, controlled trial' named entity 'post-exposure prophylaxis' named entity 'public health' named entity 'study' named entity 'Sri Lanka' named entity 'POST-EXPOSURE PROPHYLAXIS' named entity 'BASE' named entity 'PHARMACOLOGIC' named entity 'HOUSED' named entity 'PEOPLE' named entity 'STUDY' named entity 'TO PREVENT' named entity 'INCREASE' named entity 'POSITIVE' named entity 'HYDROXYCHLOROQUINE' named entity 'PUBLIC HEALTH' named entity 'PEP' named entity 'Hydroxychloroquine' named entity 'COVID' named entity 'naval personnel' named entity 'study protocol' named entity 'TAKING' named entity 'RAPID' named entity 'CONTROLLED TRIAL' named entity 'COVID' covid:arg/7956f68c85f94e19da4c42ca7e60e620f78ab61a named entity 'PEP' named entity 'hydroxychloroquine' named entity 'situation' named entity 'effectiveness' named entity 'public health' named entity 'study' named entity 'hydroxychloroquine' named entity 'Hydroxychloroquine' named entity 'naval base' named entity 'March' named entity 'coronavirus' named entity 'safety' named entity 'PEP' named entity 'REPORTED' named entity 'CAMP' named entity 'MORE THAN' named entity 'prevent' named entity 'effectiveness' named entity 'contracting'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software